ReviewFrontiers in neuroscience2014
GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence.
Review in Frontiers in neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 4 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Baclofen for alcohol use disorder.The Cochrane database of systematic reviews · 2023Pooled it
- Diagnosis and treatment of acute alcohol intoxication and alcohol withdrawal syndrome: position paper of the Italian Society on Alcohol.Internal and emergency medicine · 2019Guideline
- Baclofen for alcohol use disorder.The Cochrane database of systematic reviews · 2018Pooled it
- A DNA methylation biomarker of alcohol consumption.Molecular psychiatry · 2018Pooled it
- Neuroendocrine response to GABA-B receptor agonism in alcohol-dependent individuals: Results from a combined outpatient and human laboratory experiment.Neuropharmacology · 2018Trial
- Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety.Alcohol and alcoholism (Oxford, Oxfordshire) · 2014Trial
- Alpha-Lipoic Acid in Early-Stage Alcohol-Related Brain Damage in Rats: A Comparative Pilot Study.Molecules (Basel, Switzerland) · 2025Article
- Structural Basis of GABAAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Synaptic Mechanisms of Ethanol Tolerance and Neuroplasticity: Insights from Invertebrate Models.International journal of molecular sciences · 2024Review
- GABAergic compounds for the treatment of alcohol use disorder.International review of neurobiology · 2024Review
- Neuropharmacology of Alcohol Addiction with Special Emphasis on Proteomic Approaches for Identification of Novel Therapeutic Targets.Current neuropharmacology · 2023Article
- Review
- GABACurrent topics in behavioral neurosciences · 2022Review
- Subregional Differences in Alcohol Modulation of Central Amygdala Neurocircuitry.Frontiers in molecular neuroscience · 2022Review
- Increased Voluntary Alcohol Consumption in Mice Lacking GABAFrontiers in behavioral neuroscience · 2022Article
- GABACurrent topics in behavioral neurosciences · 2022Review
- The GABAPsychopharmacology · 2021Article
- Spinal astrocyte aldehyde dehydrogenase-2 mediates ethanol metabolism and analgesia in mice.British journal of anaesthesia · 2021Article
- Reduced motor cortex GABAMolecular psychiatry · 2021Article
- Baclofen therapeutics, toxicity, and withdrawal: A narrative review.SAGE open medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present paper summarizes the preclinical and clinical studies conducted to define the "anti-alcohol" pharmacological profile of the prototypic GABAB receptor agonist, baclofen, and its therapeutic potential for treatment of alcohol use disorder (AUD). Numerous studies have reported baclofen-induced suppression of alcohol drinking (including relapse- and binge-like drinking) and alcohol reinforcing, motivational, stimulating, and rewarding properties in rodents and monkeys. The majority of clinical surveys conducted to date-including case reports, retrospective chart reviews, and randomized placebo-controlled studies-suggest the ability of baclofen to suppress alcohol consumption, craving for alcohol, and alcohol withdrawal symptomatology in alcohol-dependent patients. The recent identification of a positive allosteric modulatory binding site, together with the synthesis of in vivo effective ligands, represents a novel, and likely more favorable, option for pharmacological manipulations of the GABAB receptor. Accordingly, data collected to date suggest that positive allosteric modulators of the GABAB receptor reproduce several "anti-alcohol" effects of baclofen and display a higher therapeutic index (with larger separation-in terms of doses-between "anti-alcohol" effects and sedation).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.